Humasis Co. Ltd.

Equities

A205470

KR7205470008

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. Other stock markets 23:00:00 25/06/2024 BST			5-day change	1st Jan Change
1,595 ^KRW	-0.19%		-9.53%	-15.43%

06-20	Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on March 18, 2024.	CI
06-20	Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on March 18, 2024.	CI

Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on March 18, 2024.

June 20, 2024 at 08:36 am

From April 1, 2024 to June 18, 2024, the company has repurchased 10,114,124 shares, representing 8.2% for KRW 18,988.16 million. With this, the company has completed the repurchase of 13,985,788 shares, representing 11.25% for KRW 26,974.42 million under the buyback announced on March 18, 2024.

Latest news about Humasis Co. Ltd.

Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on March 18, 2024.	06-20	CI
Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on March 18, 2024.	06-20	CI
Humasis Co. Ltd.'s Equity Buyback announced on March 18, 2024, has expired with 13,985,788 shares, representing 11.25% for KRW 26,974.42 million.	06-17	CI
Humasis Co. Ltd. completed the acquisition of 34.80% stake in BLADE Entertainment CO.,LTD. from Metaplex Co., Ltd. and Flake Co., Ltd.	05-20	CI
Humasis Co. Ltd. entered into an agreement to acquire 34.80% stake in BLADE Entertainment CO.,LTD. from Metaplex Co., Ltd. and Flake Co., Ltd for KRW 48 billion.	05-16	CI
Humasis Co. Ltd. announces an Equity Buyback for 17,533,607 shares.	03-18	CI
Humasis Co. Ltd. authorizes a Buyback Plan.	03-17	CI
Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on February 26, 2024.	03-14	CI
Humasis Co. Ltd.'s Equity Buyback announced on February 26, 2024, has closed with 73,304 shares.	03-13	CI
Humasis Co. Ltd. announces an Equity Buyback for 73,304 shares.	02-26	CI
Humasis Co. Ltd. authorizes a Buyback Plan.	02-24	CI
Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on May 18, 2023.	24/05/23	CI
Humasis Co. Ltd.'s Equity Buyback announced on May 18, 2023, has closed with 73,300 shares for KRW 185.45 million.	22/05/23	CI
Humasis Co. Ltd. announces an Equity Buyback for 73,300 shares.	18/05/23	CI
Humasis Co. Ltd. authorizes a Buyback Plan.	17/05/23	CI
Humasis Co. Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on September 30, 2022.	29/03/23	CI
Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on September 30, 2022.	29/03/23	CI
Humasis Co. Ltd.'s Equity Buyback announced on September 30, 2022, has expired with 301,565 shares, representing 0.24% for KRW 5,140.7 million.	28/03/23	CI
7.6% stake in Humasis Co. Ltd. from Cha, Jung Hak, Oh, Min Jung, Oh, Jung Woo and Cha, Bo Yeon.	08/02/23	CI
ArtistCosmetics. Co., Ltd. agreed to acquire 7.6% stake in Humasis Co. Ltd. from Cha, Jung Hak, Oh, Min Jung, Oh, Jung Woo and Cha, Bo Yeon for KRW 65 billion.	26/01/23	CI
Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on September 30, 2022.	28/12/22	CI
Tranche Update on Humasis Co. Ltd.'s Equity Buyback Plan announced on May 26, 2022.	25/11/22	CI
Humasis Co. Ltd.'s Equity Buyback announced on May 26, 2022, has expired with 1,456,252 shares, representing 2.74% for KRW 20,036.05 million.	24/11/22	CI
Humasis Co. Ltd. announces an Equity Buyback for KRW 20,000 million worth of its shares.	30/09/22	CI

Chart Humasis Co. Ltd.

Duration

Period

More charts

Company Profile

Humasis Co Ltd is a Korea-based company principally engaged in the manufacture and sale of in vitro diagnostic devices. The Company is engaged in the manufacture and sale of immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, cancer marker test devices and other products. In addition, the Company is engaged in the research and development of biomaterials and other products. The Company sells its products within domestic market and to overseas markets. The Company was established in 2000 and is located in Gunpo-si, Gyeonggi-do, South Korea.

Sector

Medical Equipment, Supplies & Distribution

Calendar

10/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
HUMASIS CO. LTD.	-15.43%	141M
BIOMÉRIEUX	-9.79%	11.57B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-12.79%	7.37B
LANTHEUS HOLDINGS, INC.	+26.65%	5.44B
AUTOBIO DIAGNOSTICS CO., LTD.	-17.87%	3.74B
ANDON HEALTH CO., LTD.	+7.41%	2.58B
10X GENOMICS, INC.	-65.15%	2.33B
MYRIAD GENETICS, INC.	+28.63%	2.23B
VITROLIFE AB	-11.71%	2.21B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-14.32%	1.67B

Diagnostic & Testing Substances